Merck's melanoma drug lambrolizumab among FDA 11 'breakthrough' meds
This article was originally published in Scrip
Executive Summary
Merck became the latest to reveal it had won the US FDA's breakthrough therapy designation, disclosing on 24 April it gained the status for the company's experimental antibody lambrolizumab (MK-3475), which is under investigation for advanced melanoma.